The estimated Net Worth of Richard J. Lim is at least $2.65 Milion dollars as of 27 June 2016. Richard Lim owns over 461,538 units of Paratek Pharmaceuticals stock worth over $2,647,824 and over the last 10 years Richard sold PRTK stock worth over $0.
Richard has made over 1 trades of the Paratek Pharmaceuticals stock since 2016, according to the Form 4 filled with the SEC. Most recently Richard bought 461,538 units of PRTK stock worth $5,999,994 on 27 June 2016.
The largest trade Richard's ever made was buying 461,538 units of Paratek Pharmaceuticals stock on 27 June 2016 worth over $5,999,994. On average, Richard trades about 230,769 units every 0 days since 2014. As of 27 June 2016 Richard still owns at least 1,187,365 units of Paratek Pharmaceuticals stock.
You can see the complete history of Richard Lim stock trades at the bottom of the page.
Richard's mailing address filed with the SEC is C/O PARATEK PHARMACEUTICALS, INC., 75 KNEELAND STREET, BOSTON, MA, 02111.
Over the last 10 years, insiders at Paratek Pharmaceuticals have traded over $9,410,794 worth of Paratek Pharmaceuticals stock and bought 1,743,576 units worth $13,751,429 . The most active insiders traders include James D Dondero, Bioventures Cayman Ltd Hbm a Evan Loh. On average, Paratek Pharmaceuticals executives and independent directors trade stock every 24 days with the average trade being worth of $63,310. The most recent stock trade was executed by Randall B. Brenner on 8 August 2023, trading 27,603 units of PRTK stock currently worth $60,727.
paratek pharmaceuticals (nasdaq: prtk) is a biopharmaceutical company that develops transformative solutions for patients, both in and out of the hospital, with diseases that are not responsive to current treatments. we focus on drugs that target infectious disease and other difficult to treat conditions. our lead product candidate, omadacycline, is the first in a new class of tetracyclines known as aminomethycyclines, with broad spectrum activity against gram-positive, gram-negative and atypical bacteria. omadacycline is being developed as a once daily, oral and intravenous, empiric monotherapy for community acquired bacterial infections, particularly when antibiotic resistance is of concern. the food and drug administration (fda) granted omadacycline a qualified infectious disease product (qidp) designation and completed two special protocol assessments for its phase 3 clinical trial program.
Paratek Pharmaceuticals executives and other stock owners filed with the SEC include: